InvestSMART

Price-sensitive announcement not found.

AVITA Medical, Inc. (ASX: AVH) - Announcements

- Current share price for AVH : $2.280

ASX company news and announcements for AVITA Medical, Inc. (AVH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AVITA Medical, Inc. (AVH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AVITA Medical, Inc. (AVH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AVITA Medical, Inc. (AVH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$185 Avita granted EU Patent 5 Apr 2012 10:42AM $0.225 $2.280 risen by 913.33%
$185 Half Yearly Report and Accounts 29 Feb 2012 7:08PM $0.240 $2.280 risen by 850%
$185 Successfully completes ISO Quality Recertification 9 Feb 2012 8:23AM $0.130 $2.280 risen by 1,653.85%
$185 Appendix 4C - quarterly 31 Jan 2012 8:32AM $0.135 $2.280 risen by 1,588.89%
$185 ReCell Expansion of Sales into Italy 1 Dec 2011 9:25AM $0.105 $2.280 risen by 2,071.43%
$185 IP Transfer Completed 29 Nov 2011 8:22AM $0.100 $2.280 risen by 2,180%
$185 Appendix 4C - quarterly 28 Oct 2011 3:35PM $0.100 $2.280 risen by 2,180%
$185 Launches ReCell for Treatment of Chronic Ulcers 13 Oct 2011 1:07PM $0.110 $2.280 risen by 1,972.73%
$185 ReCell JV Middle East and North Africa Launch 7 Sep 2011 9:46AM $0.110 $2.280 risen by 1,972.73%
$185 Preliminary Final Report 31 Aug 2011 9:49AM $0.095 $2.280 risen by 2,300%
$185 FDA ReCell Approval Received for Study Cosmetic Indications 25 Aug 2011 10:18AM $0.120 $2.280 risen by 1,800%
$185 Appendix 4C - quarterly 1 Aug 2011 8:22AM $0.115 $2.280 risen by 1,882.61%
$185 ReCell at Cosmedica Germany and USA Regenerative Forum 7 Jun 2011 8:28AM $0.140 $2.280 risen by 1,528.57%
$185 Share Purchase Plan Offer 20 May 2011 9:41AM $0.120 $2.280 risen by 1,800%
$185 Equity Raising and La Jolla Convertible Note termination 17 May 2011 11:51AM $0.120 $2.280 risen by 1,800%
$185 Trading Halt 16 May 2011 9:25AM $0.150 $2.280 risen by 1,420%
$185 3rd Quarter Financial Results 29 Apr 2011 11:39AM n/a $2.280 n/a
$185 Quarterly Report 29 Apr 2011 11:32AM $0.125 $2.280 risen by 1,724%
$185 Pilot Clinical Study presented at British Burns Association 27 Apr 2011 8:23AM $0.135 $2.280 risen by 1,588.89%
$185 ReCell study on healing of Acute and Chronic Wounds 20 Apr 2011 9:58AM $0.130 $2.280 risen by 1,653.85%
$185 Half Yearly Report and Accounts 25 Feb 2011 1:27PM $0.130 $2.280 risen by 1,653.85%
$185 European ISO Quality Certification 2 Feb 2011 8:25AM $0.135 $2.280 risen by 1,588.89%
$185 Appendix 4C - quarterly 31 Jan 2011 10:29AM $0.105 $2.280 risen by 2,071.43%
$185 Placement and Unmarketable Parcel update 24 Jan 2011 1:30PM $0.130 $2.280 risen by 1,653.85%
$185 China and Taiwan Update 30 Nov 2010 8:30AM $0.110 $2.280 risen by 1,972.73%

1301 - 1325 of 1362 results

Page 53 of 55

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.